scholarly journals Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan

2021 ◽  
Author(s):  
Tomoyuki Kawamura ◽  
Toru Kikuchi ◽  
Hiroshi Horio ◽  
Naveen Rathor ◽  
Magnus Ekelund
Keyword(s):  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Insulin Aspart ◽  
Efficacy And Safety ◽  
Acting Insulin ◽  
Fast Acting

scholarly journals Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial

Diabetes Care ◽  
2019 ◽  
Vol 42 (7) ◽  
pp. 1255-1262 ◽  
Author(s):  
Bruce W. Bode ◽  
Violeta Iotova ◽  
Margarita Kovarenko ◽  
Lori M. Laffel ◽  
Paturi V. Rao ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Insulin Aspart ◽  
Insulin Degludec ◽  
Efficacy And Safety ◽  
Acting Insulin ◽  
Fast Acting

scholarly journals The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes

2020 ◽  
Vol 21 (5) ◽  
pp. 781-790
Author(s):  
Torben Biester ◽  
Thekla von dem Berge ◽  
Line Quist Bendtsen ◽  
Mette Dahl Bendtsen ◽  
Naveen Rathor ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Insulin Aspart ◽  
Acting Insulin ◽  
Fast Acting

scholarly journals Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial

2018 ◽  
Vol 20 (12) ◽  
pp. 2885-2893 ◽  
Author(s):  
John B. Buse ◽  
Anders L. Carlson ◽  
Mitsuhisa Komatsu ◽  
Ofri Mosenzon ◽  
Ludger Rose ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Aspart ◽  
Insulin Degludec ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial ◽  
Acting Insulin ◽  
Fast Acting

scholarly journals Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

2018 ◽  
Vol 20 (5) ◽  
pp. 1148-1155 ◽  
Author(s):  
Chantal Mathieu ◽  
Bruce W. Bode ◽  
Edward Franek ◽  
Athena Philis‐Tsimikas ◽  
Ludger Rose ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Aspart ◽  
Phase Iii ◽  
Treat To Target ◽  
Efficacy And Safety ◽  
Phase Iii Trial ◽  
Diabetes Onset ◽  
Acting Insulin ◽  
Fast Acting

scholarly journals Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial

2018 ◽  
Vol 19 (7) ◽  
pp. 1263-1270 ◽  
Author(s):  
Tadej Battelino ◽  
Larry C. Deeb ◽  
Magnus Ekelund ◽  
Ona Kinduryte ◽  
Georgeanna J. Klingensmith ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Randomized Trial ◽  
Children And Adolescents ◽  
Insulin Aspart ◽  
Fixed Combination ◽  
Insulin Degludec ◽  
Efficacy And Safety

Glycemic Control with Fast-Acting Insulin Aspart According to Dose Adjustment Method in Type 1 Diabetes: A Post Hoc Analysis of Onset 8

2018 ◽  
Vol 42 (5) ◽  
pp. S47
Author(s):  
Rémi Rabasa-Lhoret ◽  
Thomas R. Pieber ◽  
John B. Buse ◽  
Ludger Rose ◽  
Anders Gorst-Rasmussen ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Insulin Aspart ◽  
Dose Adjustment ◽  
Post Hoc Analysis ◽  
Adjustment Method ◽  
Acting Insulin ◽  
Post Hoc ◽  
Fast Acting
Sign in / Sign up

Export Citation Format

Share Document